PURPOSE: Trastuzumab combined with chemotherapy improves outcomes for women with human epidermal growth factor receptor 2 (HER2) overexpressing advanced breast cancer. We conducted a pilot study of preoperative trastuzumab and paclitaxel, followed by surgery and adjuvant doxorubicin and cyclophosphamide chemotherapy in earlier stage breast cancer. PATIENTS AND METHODS: Patients with HER2-positive (2+ or 3+ by immunohistochemistry) stage II or III breast cancer received preoperative trastuzumab (4 mg/kg x 1, then 2 mg/kg/wk x 11) in combination with paclitaxel (175 mg/m(2) every 3 weeks x 4). Patients received adjuvant doxorubicin and cyclophosphamide chemotherapy following definitive breast surgery. Clinical and pathologic response rates were determined after preoperative therapy. Left ventricular ejection fraction and circulating levels of HER2 extracellular domain were measured serially. RESULTS: Preoperative trastuzumab and paclitaxel achieved clinical response in 75% and complete pathologic response in 18% of the 40 women on study. HER2 3+ tumors were more likely to respond than 2+ tumors (84% v 38%). No unexpected treatment-related noncardiac toxicity was encountered. Four patients developed grade 2 cardiotoxicity (asymptomatic declines in left ventricular ejection fraction). Baseline HER2 extracellular domain was elevated in 24% of patients and declined with preoperative therapy. Immunohistochemical analyses of posttherapy tumor specimens indicated varying patterns of HER2 expression following trastuzumab-based treatment. CONCLUSION: Preoperative trastuzumab and paclitaxel is active against HER2 overexpressing early-stage breast cancer and may be feasible as part of a sequential treatment program including anthracyclines. The observed changes in cardiac function merit further investigation. Correlative analyses of HER2 status may facilitate understanding of tumor response and resistance to targeted therapy.
PURPOSE:Trastuzumab combined with chemotherapy improves outcomes for women with humanepidermal growth factor receptor 2 (HER2) overexpressing advanced breast cancer. We conducted a pilot study of preoperative trastuzumab and paclitaxel, followed by surgery and adjuvant doxorubicin and cyclophosphamide chemotherapy in earlier stage breast cancer. PATIENTS AND METHODS: Patients with HER2-positive (2+ or 3+ by immunohistochemistry) stage II or III breast cancer received preoperative trastuzumab (4 mg/kg x 1, then 2 mg/kg/wk x 11) in combination with paclitaxel (175 mg/m(2) every 3 weeks x 4). Patients received adjuvant doxorubicin and cyclophosphamide chemotherapy following definitive breast surgery. Clinical and pathologic response rates were determined after preoperative therapy. Left ventricular ejection fraction and circulating levels of HER2 extracellular domain were measured serially. RESULTS: Preoperative trastuzumab and paclitaxel achieved clinical response in 75% and complete pathologic response in 18% of the 40 women on study. HER2 3+ tumors were more likely to respond than 2+ tumors (84% v 38%). No unexpected treatment-related noncardiac toxicity was encountered. Four patients developed grade 2 cardiotoxicity (asymptomatic declines in left ventricular ejection fraction). Baseline HER2 extracellular domain was elevated in 24% of patients and declined with preoperative therapy. Immunohistochemical analyses of posttherapy tumor specimens indicated varying patterns of HER2 expression following trastuzumab-based treatment. CONCLUSION: Preoperative trastuzumab and paclitaxel is active against HER2 overexpressing early-stage breast cancer and may be feasible as part of a sequential treatment program including anthracyclines. The observed changes in cardiac function merit further investigation. Correlative analyses of HER2 status may facilitate understanding of tumor response and resistance to targeted therapy.
Authors: Smitha Reddy; Calvin C Shaller; Mohan Doss; Irina Shchaveleva; James D Marks; Jian Q Yu; Matthew K Robinson Journal: Clin Cancer Res Date: 2010-12-21 Impact factor: 12.531
Authors: Soley Bayraktar; Ana M Gonzalez-Angulo; Xiudong Lei; Aman U Buzdar; Vicente Valero; Amal Melhem-Bertrandt; Henry M Kuerer; Gabriel N Hortobagyi; Aysegul A Sahin; Funda Meric-Bernstam Journal: Cancer Date: 2011-09-27 Impact factor: 6.860
Authors: Sylvia Adams; A Bapsi Chakravarthy; Martin Donach; Darcy Spicer; Stella Lymberis; Baljit Singh; Joshua A Bauer; Tsivia Hochman; Judith D Goldberg; Franco Muggia; Robert J Schneider; Jennifer A Pietenpol; Silvia C Formenti Journal: Breast Cancer Res Treat Date: 2010-09-29 Impact factor: 4.872
Authors: Hideko Yamauchi; Wendy A Woodward; Vicente Valero; Ricardo H Alvarez; Anthony Lucci; Thomas A Buchholz; Takayuki Iwamoto; Savitri Krishnamurthy; Wei Yang; James M Reuben; Gabriel N Hortobágyi; Naoto T Ueno Journal: Oncologist Date: 2012-05-14
Authors: David Sarid; Ilan G Ron; Fani Sperber; Yona Stadler; Perry Kahan; Felix Kovner; Rami Ben-Yosef; Sylvia Marmor; Yulia Grinberg; Natalie Maimon; Juliana Weinstein; Neora Yaal-Hahoshen Journal: Clin Drug Investig Date: 2006 Impact factor: 2.859
Authors: F Peintinger; A U Buzdar; H M Kuerer; J A Mejia; C Hatzis; A M Gonzalez-Angulo; L Pusztai; F J Esteva; S S Dawood; M C Green; G N Hortobagyi; W F Symmans Journal: Ann Oncol Date: 2008-07-29 Impact factor: 32.976